Expansile nanoparticles (eNPs) are novel, pH-responsive drug delivery vehicles that distinguish themselves from other polymeric, responsive systems by their swelling, tumor localization, lymphatic trafficking, and drug-depot/partitioning effect (J. Am. Chem. Soc., 2009, 131, 2469-2471; Mol. Pharm., 2012, 9, 196-200).  The eNPs utilize a physiologic pH trigger to achieve intracellular delivery whereby the eNPs undergo a change from a hydrophobic to a hydrophilic structure with subsequent release of eNP drug payload.  Previous studies have shown that IP administered, un-targeted eNPs localize to regions of mesothelial tumor and a single injection of paclitaxel loaded expansile nanoparticles (Pax-eNPs) significantly reduces overall tumor burden and prevents establishment of mesothelial (Biomaterials, 2011, 32, 832-840).  Herein, we extend our investigation of Pax-eNPs to a more rigorous animal model: the treatment of established disease.  Results show that Pax-eNPs significantly improved overall survival with animals showing a successful clinical response as compared to paclitaxel delivered via Cremophor EL.

Expansile nanoparticles successfully treat established intraperitoneal mesothelioma

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.